Patent ID: 11912776
Assignee: PFIZER INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method of treating a condition associated with malignant cells expressing B-cell maturation antigen (BCMA) in a subject comprising:
administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an engineered immune cell expressing at the surface a BCMA-specific chimeric antigen receptor (CAR) comprising an extracellular ligand-binding domain, a first transmembrane domain, and an intracellular signaling domain and wherein the extracellular ligand-binding domain comprises a single chain Fv fragment (scFv) comprising
(i) a heavy chain variable (VH) region comprising the amino acid sequence shown in SEQ ID NO: 33 and a light chain variable (VL) region comprising the amino acid sequence shown in SEQ ID NO: 34;
(ii) a heavy chain variable (VH) region comprising the amino acid sequence shown in SEQ ID NO: 112 and a light chain variable (VL) region comprising the amino acid sequence shown in SEQ ID NO: 38;
(iii) a heavy chain variable (VH) region comprising the amino acid sequence shown in SEQ ID NO: 72 and a light chain variable (VL) region comprising the amino acid sequence shown in SEQ ID NO: 73;
(iv) a heavy chain variable (VH) region comprising the amino acid sequence shown in SEQ ID NO: 39 and a light chain variable (VL) region comprising the amino acid sequence shown in SEQ ID NO: 40;
(v) a heavy chain variable (VH) region comprising the amino acid sequence shown in SEQ ID NO: 76 and a light chain variable (VL) region comprising the amino acid sequence shown in SEQ ID NO: 77;
(vi) a heavy chain variable (VH) region comprising the amino acid sequence shown in SEQ ID NO: 83 and a light chain variable (VL) region comprising the amino acid sequence shown in SEQ ID NO: 84;
(vii) a heavy chain variable (VH) region comprising the amino acid sequence shown in SEQ ID NO: 92 and a light chain variable (VL) region comprising the amino acid sequence shown in SEQ ID NO: 93;
(viii) a heavy chain variable (VH) region comprising the amino acid sequence shown in SEQ ID NO: 25 and a light chain variable (VL) region comprising the amino acid sequence shown in SEQ ID NO: 18; or
(ix) a heavy chain variable (VH) region comprising the amino acid sequence shown in SEQ ID NO: 8 and a light chain variable (VL) region comprising the amino acid sequence shown in SEQ ID NO: 80,
wherein the transmembrane domain comprises a CD8α chain transmembrane domain, and wherein the intracellular signaling domain comprises a CD3ξ signaling domain and/or a 4-1BB signaling domain.